ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/vinca-alkaloid
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/vinca-alkaloid
15
trial(s) found.
NCT07419295
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma (
TroFuse-031
)
anti-Trop2 antibody-drug conjugate
+ vinca alkaloid
Bladder cancer
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
+ vinca alkaloid
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
+ vinca alkaloid
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06401330
Paed
Phase 3
Recruiting
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (
AREN2231
)
Carboplatin
Cyclophosphamide
Dactinomycin
Doxorubicin
Etoposide
Irinotecan
Vincristine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Wilms tumour
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06333899
Paed
Phase 1
Recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
CONNECT-TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
+ vinca alkaloid
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
+ vinca alkaloid
Acute lymphoblastic leukaemia
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Cancer
NSW
2145 - Westmead - The Children's Hospital at Westmead
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (COMPLETED)
NCT05504291
Paed
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
+ vinca alkaloid
Retinoblastoma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
WA
6009 - Perth - Perth Children's Hospital
NCT05304585
Paed
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
+ vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05279300
Advanced
Phase 1
Recruiting
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas (
CS5001-101
)
anti-ROR1 antibody-drug conjugate
+ vinca alkaloid
Lymphoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide (TERMINATED)
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
+ vinca alkaloid
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
ACTRN12609000003279
Radonc
Phase 2
Recruiting
A phase II trial evaluating progression free survival with cisplatin and oral vinorelbine plus radiation for Stage III Non Small Cell Lung Cancer (
CoVERT
)
platinum-based antineoplastic agent
vinca alkaloid
Non-small cell lung cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not yet recruiting (1)
Recruitment Country and State
NSW (8)
QLD (8)
WA (8)
VIC (7)
SA (4)
NZ (4)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 2 (5)
Phase 3 (7)
Trial Type
Paed (6)
Advanced (4)
Radonc (3)
Curative (1)
Haem (1)
Cancer Therapy Class
KIT
13%
CD20
13%
Trop2
7%
PD-1/PD-L1
7%
PD-L1
7%
ERBB2
7%
ALK
7%
DPD
7%
ROS1
7%
orotate phosphoribosyltransferase
7%
BCR-ABL1
7%
CD19
7%
PDGFRA
7%
SRC
7%
YES1
7%
CDK4
7%
CDK6
7%
VEGFR2
7%
ROR1
7%
cereblon
7%
FGFR
7%
FGFR1
7%
FGFR1/2/3
7%
FGFR2
7%
FGFR3
7%
FGFR4
7%
PDGFR
7%
RET
7%
VEGFR
7%
GD2
7%
BTK
7%
Facility
6009 - Perth - Perth Children's Hospital (7)
4101 - South Brisbane - Queensland Children's Hospital (5)
2031 - Randwick - Sydney Children's Hospital (5)
2145 - Westmead - The Children's Hospital at Westmead (5)
NZ.1023 - Grafton - Starship Children's Hospital (4)
3052 - Parkville - Royal Children's Hospital Melbourne (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2305 - New Lambton Heights - John Hunter Children's Hospital (3)
2109 - North Ryde - Macquarie University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2217 - Kogarah - St George Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4032 - Chermside - The Prince Charles Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
NA
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3002 - East Melbourne - Epworth Freemasons (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3168 - Clayton - Monash Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Sarcoma
Haematological malignancy
Bladder cancer
Urogenital cancer
Wilms tumour
Neurological cancer
Leukaemia
Lymphoid leukaemia
Rhabdomyosarcoma
Soft tissue sarcoma
Lymphoma
Breast adenocarcinoma
Breast cancer
HER2-positive breast cancer
Anaplastic astrocytoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Acute lymphoblastic leukaemia
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
High-grade B-cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy